SCHEMBL6435673

SCHEMBL6435673

Fc1ccc(Nc2nc3nonc3nc2NN=Cc2ccc(-c3ccc(Cl)cc3)o2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.48
KMT2A Q03164 6/20 0.48
RAB9A P51151 4/20 0.48
NPC1 O15118 2/20 0.48
BIRC5 O15392 1/20 0.46
MAPT P10636 8/20 0.44
POLB P06746 3/20 0.44
KDM4E B2RXH2 8/20 0.43
ALDH1A1 P00352 5/20 0.43
HPGD P15428 3/20 0.43
GAA P10253 3/20 0.43
ALOX12 P18054 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
PRMT5 O14744 1/20 0.43
WDR77 Q9BQA1 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.42
TP53 P04637 2/20 0.42
L3MBTL1 Q9Y468 2/20 0.41
HTT P42858 2/20 0.41
S1PR2 O95136 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6505849 0.90 BIRC5 (0.53) MEN1KMT2ARAB9ANPC1BIRC5
SCHEMBL6505842 0.90 BIRC5 (0.53) MEN1KMT2ARAB9ANPC1BIRC5
SCHEMBL6413614 0.90 MAPT (0.46) MEN1KMT2ARAB9ANPC1BIRC5
SCHEMBL6413618 0.90 MAPT (0.46) MEN1KMT2ARAB9ANPC1BIRC5
SCHEMBL6418375 0.87 MAPT (0.52) MEN1KMT2ARAB9ANPC1BIRC5
SCHEMBL6418378 0.87 MAPT (0.52) MEN1KMT2ARAB9ANPC1BIRC5
SCHEMBL6419740 0.87 BIRC5 (0.57) MEN1KMT2ARAB9ANPC1BIRC5
SCHEMBL6419733 0.87 BIRC5 (0.57) MEN1KMT2ARAB9ANPC1BIRC5
SCHEMBL6415669 0.86 KMT2A (0.53) MEN1KMT2ARAB9ANPC1BIRC5
SCHEMBL6415667 0.86 KMT2A (0.53) MEN1KMT2ARAB9ANPC1BIRC5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 MEN1 4392/4885KMT2A 3640/4885RAB9A 1136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.